Dr Emad Anaam
After graduating with MSc in laboratory diagnosis for studying the significance of in-vitro serum biomarkers in early diagnosis of ovarian cancer, Emad was awarded a PhD scholarship from the University of Liverpool to work on the in-vitro metabolic profiling of head and neck cancer cells. Emad joined CELT as a postdoctoral research associate in 2022 to work on a project that aims to develop methods for in-vitro release testing of Long-Acting injectables (LAIs) and seeks to progress a new approach combining LAIs and microarray patches (MAPS) to simplify the therapy of various chronic diseases.
Dr Usman Arshad
Usman obtained an MSc in Drug Discovery Skills from King’s College London and a BSc in Physiology and Pharmacology with Honours from UCLAN before He undertook his CRUK funded PhD at the University of Liverpool which focused on developing nanomedicines for metastatic cancers. In his role as a post-doctoral research associate within CELT, Usman conducted research on the LONGEVITY project and various COVID-19 projects.
Dr Jennifer Blaylock
Jen completed her PhD at the University of Aberdeen and has extensive experience conducting and managing biological research and clinical trials before undertaking a role as project manager for the LONGEVITY project - a multinational collaboration aiming to develop long-acting injectable medicines for malaria prophylaxis, TB prevention and HCV therapy that forms part of the CELT project portfolio. Jen’s previous experience includes biobanking, research governance, research quality management and overseeing large research study portfolios.
Jenny joined CELT as a Senior Finance Officer supporting the LONGEVITY project to provide comprehensive budget support to all LONGEVITY partners as well as detailed monitoring and reconciliation of complex budgets. Prior to this role, she worked within the university in the Research Support Office and managed budgets for 115 Research projects across the pharmacology group.
Helen Cox has joined CELT as a full time Research Technician following a secondment with the group since October 2021. She has worked for the University of Liverpool since graduating with a BSc (Hons) in Anatomy & Human Biology in 1989, apart from a period of time in the late 1990s at Liverpool John Moores University where she completed a MPhil in muscle physiology under the supervision of Professor Dave Goldspink. Helen has gained experience, particularly in histology labs, in a wide variety of research settings including breast cancer, orthopaedics, herpes virology, lung cancer, anti-coagulant therapeutics, pancreatitis and women’s health.
Ian joined CELT as a Project Officer, providing comprehensive support to senior members of the team, across a large portfolio of research projects and related activity. Prior to this role Ian had worked with a number of other areas across the University including the School of Medicine and Institute of Population Health.
Dr Paul Curley
Paul took up a role as a Research Fellow in the Department Pharmacology and Therapeutics to focus on the development and pharmacological assessment of novel long-acting therapeutics. He developed substantial experience with multiple in vitro, in vivo and in silico methods for the assessment of nanoparticle and small molecule drug delivery and became the lead researcher for bioanalysis and in vitro testing of long-acting therapeutics within CELT. This included the development and validation of bioanalytical methods for the quantitation of therapeutics, investigating drug uptake and toxicity utilising in vitro cell systems, and in vivo disposition of small molecule and nanoformulated antiretrovirals. Paul also gained expertise in physiologically-based pharmacokinetic (PBPK) modelling and utilised this skill to predict plasma and tissue distribution of standard and long-acting antiretroviral formulations prior to preclinical and ultimately clinical in vivo studies.
Jo joined the CELT Pharmacology group to conduct work as a research technician. She previously worked for the Biomedical Services Unit for 21 years where she specialised in Containment Level 3 laboratory work.
Edyta graduated in Animal Production at University of Technology and Agriculture in Bydgoszcz, Poland before working as a scientist at Aptuit (an Evotec company) in the Department of Pharmacology. Edyta previously worked as an animal technician at University of Liverpool and at Cancer Research UK before taking up a role as a research technician for CELT.
Julie joined CELT as a Senior Finance Officer supporting the LONGEVITY project to provide comprehensive budget support to all LONGEVITY partners as well as detailed monitoring and reconciliation of complex budgets. Prior to joining the University, Julie worked within a number of public and private sector companies assisting with the financial management of externally funded projects.
Dr Megan Neary
Megan earned her PhD investigating the role of patient genetics on drug-drug interactions and drug toxicity in patients receiving antiretroviral drugs. She worked with many international collaborators and provided training in pharmacogenetics wet lab techniques and analysis at IDI Makerere University in Uganda. She then took up a postdoctoral position conducting preclinical investigations of long acting antiretroviral therapies and potential SARS-CoV-2 therapeutics in the CELT Pharmacology group. Megan was awarded a Wellcome Trust funded institutional strategic support fund to study the suitability of non-mammalian organisms for use within a preclinical drug development pipeline.
Dr Henry Pertinez
In his role as a pharmacometrician (specialist in analysis and mathematical modelling of quantitative pharmacological data), both pharmacokinetic and pharmacodynamic, Henry has conducted quantitative data analysis using various techniques such as compartmental and non-compartmental pharmacokinetic analysis, physiologically-based pharmacokinetic modelling (PBPK), deconvolution and population mixed effects analysis to provide insight into the meaning and interpretation of data, and for simulation and extrapolation of drug use scenarios.
Dr Rajith Rajoli
Rajith obtained his PhD in Pharmacology from the University of Liverpool in 2017 before undertaking a role as a Research Fellow at CELT. As a pharmacometrician, he worked on design, validation, simulation, and dose optimisation of various chemical entities using physiologically-based pharmacokinetic (PBPK) models for various routes of administration. This work has been primarily in the therapeutic areas of HIV, TB, HCV, malaria and SARS-CoV-2. His research interests focus on improving the estimation capabilities of PBPK models to better inform drug pharmacokinetics. Rajith has authored over 30 peer reviewed publication in various journals, books and review manuscripts.
Dr Jo Sharp
Jo completed her PhD at The University of Manchester in 2010 focused on the virulence and gene expression of Aspergillus fumigatus and efficacy of antifungal drugs. She has managed a number of complex projects in her role as programme manager for CELT Pharmacology, and has over 10 years’ experience of preclinical models of infection. Jo has led the preclinical evaluation team investigating antiviral candidates against SARS-CoV2 and HIV as well as novel long-acting medicines for diseases such as malaria, TB and HCV.
Andy took on the role of Science Communications & Monitoring and Evaluation Officer at CELT to lead the communications strategy and ensure research conducted by CELT scientists is shared globally to maximise impact using the website, social media and various other communication channels. He grew CELT's network by implementing a public engagement strategy to connect CELT to a worldwide audience as well as implementing cross-promotional activitiy for all CELT partners to facilitate knowledge exchange and work towards effective collaboration for key stakeholders.
Dr Lee Tatham
Lee completed his BSc in Microbiology before undertaking a PhD, investigating the antimicrobial efficacy and mode of action of solid drug nanoparticles. He held various postdoctoral positions focusing on the pharmacological assessment of novel nanoscale drug delivery systems and their application to HIV therapy. Lee has expertise in the development and application of pre-clinical models to assess the pharmacology and bio-distribution of drug-loaded nanoparticles for both oral and parenteral delivery. His research activities primarily focus on delivering the objectives of Tandem Nano Ltd. He has published a number of research articles and is co-inventor of patents relating to the application of nanotechnology to drug delivery.
After graduating from Monash University, Australia with a BSc (Hons) in Immunology, Anthony spent eight years working on hypertension, specifically the renin-angiotensin system. Anthony moved to the UK to work on the biology of the epithelia, covering development, apoptosis, stem cells and cancer. Anthony has over 25 years of experience in medical research and is an expert in 3D culture systems. He began working for CELT as a research technician to manage the day-to-day running of the CELT labs and provide technical support for his colleagues.
Shirl was appointed as Senior Research Administrator at CELT to work on the LONGEVITY Project and provides administrative support to the management team and researchers. Prior to this, she was the senior clerical officer in the Biomedical Services Unit supporting the day to day Administration of the central office and the animal unit as well as providing administrative support to the Technical Staff and Researchers.